Contrasting Recordati Industria Chimica E Farmaceutica (RCDTF) & The Competition

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) is one of 244 publicly-traded companies in the “MED – DRUGS” industry, but how does it contrast to its peers? We will compare Recordati Industria Chimica E Farmaceutica to related companies based on the strength of its profitability, earnings, analyst recommendations, valuation, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Recordati Industria Chimica E Farmaceutica and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Recordati Industria Chimica E Farmaceutica	$2.53 billion	$450.70 million	32.72
Recordati Industria Chimica E Farmaceutica Competitors	$1.08 billion	$58.12 million	-5.74

Recordati Industria Chimica E Farmaceutica has higher revenue and earnings than its peers. Recordati Industria Chimica E Farmaceutica is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

44.3% of shares of all “MED – DRUGS” companies are owned by institutional investors. 13.8% of shares of all “MED – DRUGS” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Recordati Industria Chimica E Farmaceutica and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Recordati Industria Chimica E Farmaceutica	18.65%	31.05%	13.16%
Recordati Industria Chimica E Farmaceutica Competitors	-19,902.74%	-91.90%	-26.01%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Recordati Industria Chimica E Farmaceutica and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recordati Industria Chimica E Farmaceutica	1	1	0	0	1.50
Recordati Industria Chimica E Farmaceutica Competitors	1219	3365	9113	325	2.61

As a group, “MED – DRUGS” companies have a potential upside of 153.76%. Given Recordati Industria Chimica E Farmaceutica’s peers stronger consensus rating and higher possible upside, analysts clearly believe Recordati Industria Chimica E Farmaceutica has less favorable growth aspects than its peers.

Risk & Volatility

Recordati Industria Chimica E Farmaceutica has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, Recordati Industria Chimica E Farmaceutica’s peers have a beta of 0.53, indicating that their average stock price is 47% less volatile than the S&P 500.

Summary

Recordati Industria Chimica E Farmaceutica peers beat Recordati Industria Chimica E Farmaceutica on 7 of the 13 factors compared.

Recordati Industria Chimica E Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.